Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase Ib/II study

被引：0
|
作者：
Ciruelos, E. M. [1 ]
Hamilton, E. P. [2 ]
Kim, S-B. [3 ]
Im, Y-H. [4 ,5 ]
Solis, E. Segui [6 ]
Saenz, J. A. Garcia [7 ]
Di Sanzo, A. [8 ]
Lizarbe, M. Dominguez [9 ]
Wasserman, T. [10 ]
Theall, K. P. [11 ]
Ibrahim, N. K. [12 ]
机构：
[1] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain
[2] Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA
[3] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[4] Sungkyunkwan Univ, Med Dept Hematol, Samsung Med Ctr SMC, Sch Med, Seoul, South Korea
[5] Sungkyunkwan Univ, Med Oncol Div, Samsung Med Ctr SMC, Sch Med, Seoul, South Korea
[6] Hosp Clin August Pi Sunyer Biomed Res Inst IDIBAP, Dept Med Oncol, Barcelona, Spain
[7] Inst Invest Sanitaria Hosp Clinico San Carlos, Dept Med Oncol, Madrid, Spain
[8] Biostatist & Data Management Dept, Menarini Grp, Florence, Italy
[9] Menarini Grp, Clin Res Dept, Florence, Italy
[10] Global Med Affairs Dept, Menarini Grp, Florence, Italy
[11] Global Product Dev Dept, Menarini Grp, New York, NY USA
[12] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol Dept, Houston, TX USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.312
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
364P
引用
收藏
页码：S370 / S370
页数：1
相关论文
共 50 条
  • [11] ELONA: An open-label, phase 1b-2 study of elacestrant, in combination with onapristone in patients with estrogen receptor-positive, progesterone receptor-positive, HER2-negative advanced or metastatic breast cancer
    Hamilton, Erika
    Pusztai, Lajos
    Soliman, Hatem H.
    Hurvitz, Sara
    Grzegorzewski, Krzysztof
    Habboubi, Nassir
    Marreddy, Priya
    Sahmoud, Tarek
    Ibrahim, Nuhad
    CANCER RESEARCH, 2023, 83 (05)
  • [12] Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis.
    Juric, Dejan
    Munster, Pamela N.
    Campone, Mario
    Ismail-Khan, Roohi
    Garcia-Estevez, Laura
    Hamilton, Erika Paige
    Becerra, Carlos
    De Boer, Richard H.
    Hui, Rina
    Goncalves, Anthony
    Wang, Yingbo
    Dhuria, Shyeilla V.
    Kalimi, Ghulam H.
    Lorenc, Karen Cristina Rodriguez
    Mayer, Ingrid A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [13] A novel scoring system based on the clinical and genomic variables to predict the early relapse in estrogen receptor-positive/HER2-negative (ER+/HER2-) breast cancer
    Lin, Caijin
    Wu, Jiayi
    Ding, Shuning
    Andriani, Lisa
    Chen, Weilin
    Liu, Deyue
    Zhu, Li
    CANCER RESEARCH, 2020, 80 (04)
  • [14] The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study
    Lim, Elgene
    Boyle, Frances
    Okera, Meena
    Loi, Sherene
    Goksu, Sema Sezgin
    van Hal, Gertjan
    Hartman, Daisy G.
    Gable, Jonathon Colby
    Price, Gregory L.
    Hossain, Anwar
    Gainford, M. C.
    Ezquerra, Meritxell Bellet
    CANCER RESEARCH, 2020, 80 (04)
  • [15] The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study
    Lim, Elgene
    Boyle, Frances
    Okera, Meena
    Loi, Sherene
    Goksu, Sema S.
    van Hal, Gertjan
    Gable, Jonathon C.
    Price, Gregory L.
    Hossain, Anwar
    Gainford, Mary
    Ezquerra, Meritxell B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 124 - 125
  • [16] A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor-positive (ER+)/HER2-negative (HER2-) breast cancer
    Borges, Virginia F.
    Chan, Arlene
    Lin, Nancy U.
    Tonda, Margaret Eleanor
    Shilkrut, Mark
    Alemany, Carlos A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [17] A phase I trial of the PI3K inhibitor (PI3Ki) copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer
    Ma, Cynthia
    Luo, Jingqin
    Moss, Jessica
    Kwa, Maryann
    Parajuli, Ritesh
    Khoury, Katia
    Douglas, Emily
    Frith, Ashley
    Rigden, Caron
    Ademuyiwa, Foluso
    Thomas, Shana
    Haas, Brittney
    Wulf, Gerburg
    Dees, Claire
    Said, Rabih
    CANCER RESEARCH, 2024, 84 (09)
  • [18] A phase II open label study of everolimus in combination with antiestrogen therapy in hormone receptor-positive HER2-negative advanced breast cancer
    Yardley, Denise A.
    Shastry, Mythili
    DeBusk, Laura M.
    Burris, Howard A., III
    Hainsworth, John D.
    CANCER RESEARCH, 2015, 75
  • [19] Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2-BC).
    Munster, Pamela N.
    Hamilton, Erika Paige
    Franklin, Catherine
    Bhansali, Suraj
    Wan, Kitty
    Hewes, Becker
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [20] A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
    Yardley, Denise A.
    Liggett, William
    Mainwaring, Mark
    Castrellon, Aurelio
    Blakely, Laura
    Hemphill, Brian
    Anz, Bertrand, III
    Young, Robyn R.
    Shastry, Mythili
    DeBusk, Laura M.
    Hainsworth, John D.
    Burris, Howard A., III
    CLINICAL BREAST CANCER, 2020, 20 (02) : 89 - 97
12345